A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial

(2013) Alexander M.M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment

(2012) P.F. Ferrucci et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases

(2012) Alessandro Neri et al.   HUMAN PATHOLOGY

How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?

(2012) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma

(2011) Jeffrey H. Dunn et al.   CANCER LETTERS

Plasma Markers for Identifying Patients with Metastatic Melanoma

(2011) H. M. Kluger et al.   CLINICAL CANCER RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

(2010) William K. Oh et al.   CANCER

Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

(2010) M. J. Besser et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN- 2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

(2009) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Reply to A. Balmanoukian et al

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival

(2009) Charlotte Aaberg-Jessen et al.   JOURNAL OF NEURO-ONCOLOGY

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

(2009) Evangelos Terpos et al.   LEUKEMIA RESEARCH

The prognostic value of TIMP-1 in multiple myeloma

(2009) Liliana Guedez et al.   LEUKEMIA RESEARCH

Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis

(2009) Y Valle et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

TIMP-1 as a tumor marker in breast cancer – An update

(2008) Sidse Ø Würtz et al.   ACTA ONCOLOGICA